So I've been looking at what could be solid plays in healthcare right now, and honestly two stocks keep coming up in my radar for anyone looking to build positions without needing massive capital. The thing is, you don't need thousands to start investing anymore. With fractional shares widely available, even a hundred bucks can get you into some quality best medical stocks.

Let me break down Pfizer first. Yeah, I know the narrative around it has been rough. The COVID windfall from Comirnaty and Paxlovid dried up faster than everyone expected, and that hit their topline hard. Guidance disappointments didn't help either. On the surface, looks like a beaten-down story. But here's what matters: they used those peak years strategically. They dropped $43 billion to acquire Seagen, a cancer-focused company. That's not random spending—that's building for the next decade.

The pipeline they've built is actually pretty deep now. New drug approvals have been rolling through consistently, and they're sitting on enough cash to weather the transition. Plus they're yielding nearly 6% as a dividend stock, which is solid for anyone looking for income alongside growth. At those levels a couple years back, you could grab multiple shares with a hundred bucks. That's the kind of entry point that matters for long-term wealth building.

Then there's Doximity. It's basically the professional network for doctors—think communication tools, research access, telemedicine, job boards. It's become essential infrastructure in healthcare. Yeah, growth slowed down compared to what it was. Revenue growth hit 11% year-over-year in their latest quarter, which sounds modest until you realize the margins are insane. We're talking 40%+ adjusted net profit margins. That's the kind of profitability that tells you something is working.

What really matters though is the moat they've built. Over 80% of US physicians are on the platform. More than 90% of graduating med students. The top 20 pharma companies and top 20 health systems all use it to reach doctors. That's not just a user base, that's a lock-in. The network effect here is real, and it keeps getting stronger. They're estimating an $18.5 billion addressable market, and they're only scratching the surface of it. For investors hunting best medical stocks with staying power, this is the kind of structural advantage that compounds over time.

Both of these play into a bigger theme in healthcare—consolidation, innovation, and digital transformation. Whether you're looking at traditional pharma pivoting to new drugs or healthcare infrastructure becoming digital-first, these sectors have real tailwinds. If you're thinking about healthcare exposure and don't have massive capital to deploy, these are worth digging into.